CFA trials for osteoarthritis
Two RCTs evaluated the role of CFAs in treating osteoarthritis of the knee. In both trials, the medication was well tolerated with no serious side-effects.
In the first trial, 64 participants were randomly assigned to receive either active capsules (350 mg of CFAs) or placebo capsules six times a day for 68 days. Participants were asked to continue taking their regular medication during the trial.
- Neither group reported improvement in knee extension.
- Participants in the active treatment group had significantly increased knee flexion.
Participants in the second trial were randomly selected to receive either CFA cream or a placebo cream. All 40 participants were asked to apply the cream to their knee twice a day for 30 days.
- Those in the active treatment group experienced significant improvement in climbing stairs and standing up from a sitting position.
- The overall range of motion of the knee was markedly improved in participants who used CFA cream.
‡ A trial of low quality. Results of this trial were given a lower weighting when we came to our conclusion about the compound.